New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For JNJ;VRTX;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 13, 2015
15:22 EDTVRTXVertex CEO says 'way too early' to talk about pricing for new CF combo drug
Vertex CEO Jeff Leiden speaking on CNBC.
14:15 EDTBMYBristol-Myers treatment of acute myeloid leukemia gets FDA orphan designation
According to a post on the FDA's website, Bristol-Myers' treatment of acute myeloid leukemia, ulocuplumab, received orphan designation. Reference Link
12:27 EDTBMYDOJ, EPA report proposed settlement regarding cleanup of Warren County, NJ site
Subscribe for More Information
10:00 EDTJNJJanssen Biotech announces license agreement with Vedanta Biosciences
Subscribe for More Information
08:09 EDTBMYBristol-Myers price target raised to $72 from $66 at Leerink
Leerink raised its price target for Bristol-Myers to $72 saying the earlier stop of the Opdivo trial affirms the drug's potential survival benefits across multiple cancers. Leerink says it now has increased confidence in positive readouts for Bristol's upcoming survival studies in non-squamous non-small cell lung cancer and kidney cancer. The firm reiterates an Outperform rating on the stock.
08:05 EDTBMYBristol-Myers Eli Lilly enter clinical collaboration pact for Opdivo combo
Subscribe for More Information
07:45 EDTJNJFierce Biotech to hold a breakfast meeting
Subscribe for More Information
07:42 EDTBMYJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
07:36 EDTVRTXVertex price target raised to $146 from $125 at Piper Jaffray
Piper Jaffray raised its price target for Vertex Pharmaceuticals shares to $146 citing continued Kalydeco growth after the company issued 2015 guidance. Piper reiterates an Overweight rating on Vertex.
January 12, 2015
09:00 EDTBMYBristol-Myers price target raised to $70 from $62 at Argus
Subscribe for More Information
08:37 EDTJNJ, BMYShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:15 EDTBMYSeattle Genetics announces clinical trial collaboration with Bristol-Myers
Subscribe for More Information
08:06 EDTBMYBristol-Myers shares expected to trade up around 10% at JPMorgan
JPMorgan expects shares of Bristol-Myers to trade up around 10% after the company announced that its Phase III trial of Opdivo in 2L squamous non-small cell lung cancer is stopping early due to efficacy. The firm views the news as a "clear positive" that sets up a potential 2015 filing and launch for the product in the 2L squamous market. It reiterates an Overweight rating on shares of the Bristol-Myers. The stock is up 7% to $64.25 in pre-market trading.
07:21 EDTJNJEBD Group to hold a conference
Subscribe for More Information
05:26 EDTBMYBristol-Myers up 5.6% after Opdivo Phase 3 study meets primary endpoint
Subscribe for More Information
05:06 EDTBMYBristol-Myers Opdivo Phase 3 study met primary endpoint
Bristol-Myers Squibb announced that an open-label, randomized Phase 3 study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer, or NSCLC, was stopped early because an assessment conducted by the independent Data Monitoring Committee, or DMC, concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company will share these data – which for the first time indicate a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer – with health authorities. CheckMate -017 investigators are being informed of the decision to stop the comparative portion of the trial. Bristol-Myers Squibb is working to ensure that eligible patients will be informed of the opportunity to continue or start treatment with Opdivo in an open-label extension as part of the company’s commitment to providing patient access to Opdivo, and characterizing long-term survival. The company will complete a full evaluation of the final CheckMate -017 data and work with investigators on the future presentation and publication of the results.
January 11, 2015
21:04 EDTVRTXVertex expects Q4 Kalydeco revenue $460M
Subscribe for More Information
21:03 EDTVRTXVertex sees 2015 Kalydeco revenue $560M-$580M
Vertex expects that its combined non-GAAP R&D and SG&A expenses in 2015 will be in the range of $1.05B-$1.1B. It said the increase as compared to 2014 is primarily a result of launch preparation activities for lumacaftor in combination with ivacaftor and the planned pivotal Phase 3 development program for VX-661 in combination with ivacaftor. Vertex's expected non-GAAP R&D and SG&A expenses exclude stock-based compensation expense and certain other expenses recorded in 2015. Vertex said entered 2015 with approximately $1.4B in cash, cash equivalents and marketable securities. Anticipated 2015 Kalydeco net revenues reflect: Use of KALYDECO by eligible patients in Australia following the completion of reimbursement discussions in late 2014; Use of KALYDECO in people in the United States with the R117H mutation following FDA approval in late 2014; The completion of reimbursement discussions for gating mutations in certain European countries; Use of KALYDECO in children with CF ages 2 to 5 with the G551D or other gating mutations in the United States, based on potential approval in March 2015.
21:00 EDTVRTXVertex says NDA for combination of lumacaftor, ivacaftor accepted by FDA
Subscribe for More Information
20:57 EDTVRTXVertex says NDA for ivacaftor use in children accepted by FDA
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use